A new drug to treat Alzheimer’s disease was approved by the U.S. Food and Drug Administration on Tuesday. In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking decline among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including swelling and bleeding in the brain. “Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer’s disease, who urgently need effective treatment options. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and Read More